Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy GW Pharmaceuticals stock | $97.04

Own GW Pharmaceuticals stock in just a few minutes.

Fact checked

GW Pharmaceuticals plc is a drug manufacturers-general business based in the US. GW Pharmaceuticals shares (GWPH) are listed on the NASDAQ and all prices are listed in US Dollars. GW Pharmaceuticals employs 901 staff and has a trailing 12-month revenue of around USD$488.1 million.

How to buy shares in GW Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for GW Pharmaceuticals. Find the stock by name or ticker symbol: GWPH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until GW Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$97.04, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of GW Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of GW Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

GW Pharmaceuticals share price

Use our graph to track the performance of GWPH stocks over time.

GW Pharmaceuticals shares at a glance

Information last updated 2021-01-14.
Latest market closeUSD$97.04
52-week rangeUSD$67.98 - USD$144
50-day moving average USD$124.2655
200-day moving average USD$114.3266
Wall St. target priceUSD$182.5
PE ratio 91.1417
Dividend yield N/A (0%)
Earnings per share (TTM) USD$1.065

Buy GW Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy GW Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

GW Pharmaceuticals price performance over time

Historical closes compared with the close of $97.04 from 2020-10-22

1 week (2021-01-08) -24.31%
1 month (2020-12-16) -15.88%
3 months (2020-10-16) 1.64%
6 months (2020-07-16) -28.32%
1 year (2020-01-15) -17.07%
2 years (2019-01-15) -24.51%
3 years (2018-01-12) 131.97
5 years (2016-01-15) 78.42%

Is GW Pharmaceuticals under- or over-valued?

Valuing GW Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GW Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

GW Pharmaceuticals's P/E ratio

GW Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 91x. In other words, GW Pharmaceuticals shares trade at around 91x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

GW Pharmaceuticals's PEG ratio

GW Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.37. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GW Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

GW Pharmaceuticals financials

Revenue TTM USD$488.1 million
Gross profit TTM USD$284.1 million
Return on assets TTM -3.49%
Return on equity TTM -7.42%
Profit margin -11.05%
Book value $23.554
Market capitalisation USD$3.9 billion

TTM: trailing 12 months

Shorting GW Pharmaceuticals shares

There are currently 3.3 million GW Pharmaceuticals shares held short by investors – that's known as GW Pharmaceuticals's "short interest". This figure is 7.1% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting GW Pharmaceuticals shares can be evaluated.

GW Pharmaceuticals's "short interest ratio" (SIR)

GW Pharmaceuticals's "short interest ratio" (SIR) is the quantity of GW Pharmaceuticals shares currently shorted divided by the average quantity of GW Pharmaceuticals shares traded daily (recently around 353342.32008593). GW Pharmaceuticals's SIR currently stands at 9.31. In other words for every 100,000 GW Pharmaceuticals shares traded daily on the market, roughly 9310 shares are currently held short.

However GW Pharmaceuticals's short interest can also be evaluated against the total number of GW Pharmaceuticals shares, or, against the total number of tradable GW Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GW Pharmaceuticals's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 GW Pharmaceuticals shares in existence, roughly 90 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable GW Pharmaceuticals shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against GW Pharmaceuticals.

Find out more about how you can short GW Pharmaceuticals stock.

GW Pharmaceuticals share dividends

We're not expecting GW Pharmaceuticals to pay a dividend over the next 12 months.

GW Pharmaceuticals share price volatility

Over the last 12 months, GW Pharmaceuticals's shares have ranged in value from as little as $67.98 up to $144. A popular way to gauge a stock's volatility is its "beta".

GWPH.US volatility(beta: 2.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GW Pharmaceuticals's is 2.1507. This would suggest that GW Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

GW Pharmaceuticals overview

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site